IN

Integrated Diagnostics

- PRIVATE:INTEGRATEDDIAGNOSTICS
For additional historical data visit
thinknum.com/demo

Linkedin Profile Data

Request demo
# Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Ticker Sector Ticker Industry
1 private:integrateddiagnostics 1655330 Dec 16th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 16th, 2017 12:00AM Dec 16th, 2017 02:21PM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
2 private:integrateddiagnostics 1655330 Dec 17th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 17th, 2017 12:00AM Dec 17th, 2017 08:12AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
3 private:integrateddiagnostics 1655330 Dec 18th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 18th, 2017 12:00AM Dec 18th, 2017 10:19AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
4 private:integrateddiagnostics 1655330 Dec 19th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 19th, 2017 12:00AM Dec 19th, 2017 05:03AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
5 private:integrateddiagnostics 1655330 Dec 21st, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 21st, 2017 12:00AM Dec 21st, 2017 12:42PM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
6 private:integrateddiagnostics 1655330 Dec 22nd, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 22nd, 2017 12:00AM Dec 22nd, 2017 05:53AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
7 private:integrateddiagnostics 1655330 Dec 23rd, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 23rd, 2017 12:00AM Dec 23rd, 2017 09:37AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
8 private:integrateddiagnostics 1655330 Dec 24th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 24th, 2017 12:00AM Dec 24th, 2017 01:22PM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
9 private:integrateddiagnostics 1655330 Dec 25th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 25th, 2017 12:00AM Dec 25th, 2017 10:21AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
10 private:integrateddiagnostics 1655330 Dec 26th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 26th, 2017 12:00AM Dec 26th, 2017 07:22AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services

Showing a preview of 94 rows

Get a demo to see more examples from the Linkedin Profile dataset.